Ovarian cancer is the most lethal cancer of the female reproductive system. In that regard, several epidemiological studies suggest that long-term exposure to estrogen could increase ovarian cancer risk, although its precise role remains controversial. To decipher a mechanism for this, we previously generated a mathematical model of how estrogen-mediated upregulation of the transcription factor, E2F6, upregulates the ovarian cancer stem/initiating cell marker, c-Kit, by epigenetic silencing the tumor suppressor miR-193a, and a competing endogenous (ceRNA) mechanism. In this study, we tested that previous mathematical model, showing that estrogen treatment of immortalized ovarian surface epithelial cells upregulated both E2F6 and c-KIT, but downregulated miR-193a. Luciferase assays further confirmed that microRNA-193a targets both E2F6 and c-Kit. Interestingly, ChIP-PCR and bisulphite pyrosequencing showed that E2F6 also epigenetically suppresses miR-193a, through recruitment of EZH2, and by a complex ceRNA mechanism in ovarian cancer cell lines. Importantly, cell line and animal experiments both confirmed that E2F6 promotes ovarian cancer stemness, whereas E2F6 or EZH2 depletion derepressed miR-193a, which opposes
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| INTRODUC TI ON
Ovarian cancer is the leading cause of death from gynecologic malignancies, and the second most common cause of all-cancer death, in women.
1 Most ovarian cancer patients are diagnosed in late stages, with poor prognosis and short life span, [2] [3] [4] due to drug resistance originating from cancer-initiating cells. Ovarian cancerinitiating cells are characterized by cell surface expression of CD44
and CD117 (ie c-KIT), a phenotype first identified by us, 5 and then others. 6, 7 Estrogen, an essential steroid nuclear hormone intimately involved in the growth and differentiation of normal ovaries, 8 has also been implicated in ovarian tumorigenesis. 9 However, antiestrogen therapies have shown only moderate efficacy against ovarian cancer, 10 and precisely how this hormone contributes to ovarian cancer stemness remains unclear. Consequently, understanding these "missing links" would provide better understanding of the origin of ovarian cancer, and thus, development of better-targeted therapies for this deadly disease.
In addition to altered endocrine signaling, aberrant epigenetic events, including dysregulated DNA methylation, histone modifications, and noncoding RNA translational modulation, are now considered a hallmark of cancer. [11] [12] [13] Furthermore, both we and others previously reported aberrant promoter DNA hypermethylation of tumor suppressor genes in numerous human cancers, including ovarian. 14-16 Specific repressive histone "marks" likewise silence tumor suppressor genes, and the histone methyltransferases EZH2 and G9a have both been found to be oncogenes.
17
To link anomalous epigenetic modifications to estrogenmediated ovarian carcinogenesis, we recently developed a mathematical model of the progression of this maglignancy. 18 In this model, we hypothesized a mechanism for estrogen-mediated upregulation of the cell cycle regulator and transcriptional repressor E2F6. 
| Patient samples
One hundred and eighteen ovarian tissue samples, including 108 cancer and 10 benign tissues, were obtained from Tri-Service General Hospital, Taipei, Taiwan (Table S1 ). 
| In vivo tumorigenicity assay

| Combined bisulfite restriction analysis and bisulphite pyrosequencing
Genomic DNA (0.5 μg) was bisulphite-modified using EZ DNA Methylation Kits (Zymo Research, Orange, CA, USA), according to the manufacturer's protocol. For combined bisulfite restriction analysis assays, bisulphite-modified DNA was subjected to PCR amplification, and 8 μL of the resultant PCR products was then digested by the restriction endonuclease AciI (New England BioLabs, Beverly, MA, USA), at 37°C, for 2 hours. For bisulphite pyrosequencing analysis, bisulphite-modified DNA was subjected to a PCR amplification strategy using a tailed reverse primer in combination with a biotin-labeled universal primer, as previously described. 16 The PCR and sequencing primers were designed using PyroMark Assay Design 2.0 (Qiagen, Hilden, Germany).
Pyrosequencing was carried out on a PyroMark Q24 (Qiagen) instrument using Pyro Gold Reagents (Qiagen) according to the manufacturer's protocol. Methylation percentages for each cytosine were then determined as the fluorescence intensity of cytosines divided by the sum of the fluorescence intensity of cytosines and thymines, at each CpG site. In vitro-methylated DNA (Millipore) was included as a positive control for pyrosequencing. All primer sequences are listed in Table S2 . Additional Material and Methods can be found in Document S1.
| Bioinformatic and statistical analysis
| RE SULTS
| Competing endogenous RNA regulation of E2F6 and c-KIT through miR-193a
Our previous mathematical model predicted that miR-193a targets c-KIT and E2F6, such that they might act as ceRNAs ( Figure 1A) to positively regulate one another. Figure 1G ) and c-KIT ( Figure 1H) ; IOSE cells treated with BPA and E2 for 3 days also significantly downregulated miR-193a ( Figure 1I ). Taken together, these results agree with our previous model that E2F6 might suppress miR-193a transcription through epigenetic modifications. However, it is noteworthy to point out that SKOV3 with low expression of EZH2 also underexpressed miR-193a but had the highest level of miR-193a promoter methylation. One explanation for this is that E2F6 might be able to directly recruit DNMT3b to epigenetically suppress miR-193a independent of EZH2, as previously reported. 
| Roles of E2F6 and EZH2 in ovarian cancer stemness
Next, the roles of E2F6 and EZH2 in ovarian cancer progenitor function were investigated. Genetic depletion of either EZH2 or E2F6 significantly inhibited CP70 cell sphere formation ( Figure 4D ), and numbers of dye-excluding cells (or side populations) ( Figure S5A ), two common stemness assays. 28, 29 Similarly, pharmacological inhibition of EZH2, by GSK343 or GSK126, likewise reduced the number of CP70 side population cells ( Figure S5B ). Finally, EZH2 or E2F6 depletion inhibited in vivo invasion ( Figure S5C ) and s.c. (Figure 4E,F) and i.p. tumor growth ( Figure S5D ). Together, the above results indicate that EZH2 and E2F6 contribute to cancer stemness, invasion, and tumor growth in ovarian cancer through epigenetic suppression of miR-193a ( Figure 3C ).
| Clinical significance of miR-193a DNA methylation in ovarian cancer patients
We next assessed the clinical significance of miR-193a methylation in human ovarian cancer (Table S3) Table S4 ). To further validate these findings, RNA sequencing data from a ovarian cancer dataset (The Cancer Genome Atlas, https://cancergenome.
nih.gov/), from 367 ovarian cancer patient samples, showed that higher expression of EZH2, E2F6, and c-KIT was observed in tumor with higher stage and grade ( Figure S6 ). Importantly, E2F6 levels positively correlated with expression of EZH2 ( Figure 5E ).
Interestingly, our previous study also reported positive correlation between the expression of E2F6 and c-KIT in ovarian cancer patients with low EZH2 levels. 18 Taken together, these results indicate that miR-193a is epigenetically silenced in ovarian cancer, and the miR-193a targets, E2F6 and c-KIT, show a ceRNA relationship.
| D ISCUSS I ON
Although several studies now suggest that activation of the estrogen receptor (ER)-α signaling pathway is intimately involved in ovarian carcinogenesis, its precise role remains controversial. For example, epidemiological studies found that women treated with hormone Figure 5 ). Importantly, cells depleted of EZH2 or E2F6 had significantly impaired stemness-associated spheres, 36 and "side population" cell formation, 37 due to downregulation of the stemness marker c-KIT by restoration of miR-193a and the ceRNA network.
In conclusion, we propose a model that the tumor suppressor function of miR-193a can be epigenetically silenced, bimodally, in ovarian cancer ( Figure 6 ). As shown, estrogen or xenoestrogens could upregulate the cell cycle-associated transcriptional repressor, E2F6, resulting in upregulation of c-KIT, through E2F6-mediated epigenetic silencing of miR-193a. Alternatively, E2F6 might act through a ceRNA mechanism, 19,20 depending on EZH2 expression. E2F6 upregulation might therefore promote cancer stemness in ovarian cancer, thus advancing tumor progression. We therefore propose that epigenetic intervention could be a novel strategy for ovarian cancer patients, especially those not responding to checkpoint inhibitors or traditional chemotherapies. 38 However, it is also noteworthy to point out that EZH2 has recently been found to be an important factor in promoting T-cell differentiation. 39 Therefore, an optimal dosage of EZH2 inhibitor in cancer treatment, without affecting T cell function, should be considered. Overall, these results are significant to suggest the involvement of ceRNA networks in tumor progression and stemness. 
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